Trametinib is a selective mitogen activated protein kinase (MEK1/MEK2) inhibitor that inhibits tumor cell proliferation and survival by blocking the activity of MEK protein in the RAS/RAF/MEK/ERK signaling pathway.

1. Drug name

Common name: Trimetanib

English name: Trametinib

Product Name: Mekinist

2. Indications

Qumeitinib is suitable for the treatment of melanoma, non-small cell lung cancer, anaplastic thyroid cancer, advanced solid tumors, and low-grade gliomas confirmed by FDA approved testing methods to have BRAFV600E or V600K mutations.

3. Specifications and characteristics

Specification: 2mg tablet.

4. Main components

The active ingredient is trametinib.

5. Usage and dosage

Adult dose: The recommended dose is 2mg, taken orally once daily.

Children's dosage: The dosage should be adjusted according to body weight.

Usage: It should be taken on an empty stomach, at least 1 hour before meals or at least 2 hours after meals.

6. Dose adjustment

Dose adjustment should be made based on the severity of adverse reactions, and in severe cases, the medication should be permanently discontinued.

7. Medication precautions

Before and after meals: It should be taken on an empty stomach, at least 1 hour before or 2 hours after meals.

Missed dose: If missed once and less than 12 hours before the next dose, skip this dose and take the next dose according to the original plan.

Vomiting: If vomiting occurs after taking medication, do not take the next dose as scheduled.

8. Medication for special populations

Patients with liver dysfunction: Mild cases do not require dose adjustment, while moderate to severe cases require close monitoring.

Patients with renal insufficiency: No need to adjust dosage.

Elderly: No need to adjust dosage, but kidney function needs to be monitored.

Pregnant and lactating women: Pregnant women are prohibited from using it, which may cause harm to the fetus; Breastfeeding women should stop breastfeeding if they need to use it.

Pediatric medication: Children aged 1 year and above with low-grade gliomas should adjust their dosage according to their weight.

9. Adverse reactions

Common adverse reactions include rash, diarrhea, lymphedema, fever, fatigue, nausea, vomiting, hypertension, peripheral edema, abnormal liver function, etc.

Serious adverse reactions require immediate medical attention.

10. Contraindications

There are no specific contraindications.

11. Drug interactions

Trimetanib is a substrate of CYP3A4 and should be avoided in combination with potent or moderate acting CYP3A4 inducers or inhibitors.

12. Storage method

Tablets: Store in the dark at 2 ℃ to 8 ℃.

Mekinistinformation